This is a previously recorded episode of The BioCentury Show. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes.

Within the framework of target, modality and path to clinic, causal biology is the axis along which Head of Research Robert Plenge is building and prosecuting research at Bristol Myers. It maps from late-stage decisions the company has made, such as the Karuna acquisition, to strategies in early R&D, such as how to innovate in ADCs and extend the modality to new applications.
In conversation with Editor in Chief Simone Fishburn on The BioCentury Show, Plenge outlined his view of causal biology as a principal axiom for building an R&D engine to maximize probability of success. It is the foundation for step one — picking the right target — and sets the basis for the second and third tenets of his framework, finding the right therapeutic modality for a mechanism of action, and establishing a clear path to clinical proof of concept.

View full story: https://www.biocentury.com/article/652135

#biotech #biopharma #pharma #lifescience

00:00 - Intro
01:53 - BMS's Framework for Research
12:38 - First vs. Best in Class
16:09 - Modalities & Manufacturing
19:48 - CAR Ts & Autoimmunity
24:34 - ADCs